Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Shares Outstanding (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Shares Outstanding for 7 consecutive years, with $8.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 73.48% to $8.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.3 million, a 73.48% increase, with the full-year FY2024 number at $5.9 million, up 221.15% from a year prior.
  • Shares Outstanding was $8.3 million for Q3 2025 at Vivos Therapeutics, up from $7.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $23.0 million in Q3 2021 to a low of $920592.0 in Q4 2021.
  • A 5-year average of $7.1 million and a median of $3.4 million in 2024 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: soared 9109.76% in 2021, then tumbled 95.96% in 2022.
  • Vivos Therapeutics' Shares Outstanding stood at $920592.0 in 2021, then changed by 0.0% to $920592.0 in 2022, then surged by 99.21% to $1.8 million in 2023, then skyrocketed by 221.15% to $5.9 million in 2024, then skyrocketed by 40.37% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Shares Outstanding are $8.3 million (Q3 2025), $7.3 million (Q2 2025), and $5.9 million (Q1 2025).